Skip to main navigation Skip to search Skip to main content

A hemostasis study in CAPD patients during fibrinolytic intraperitoneal therapy with urokinase (UK)

  • P Strippoli
  • , D Pilolli
  • , Geltrude Mingrone
  • , A Dimaggio
  • , F Coviello
  • , G Orbello
  • , M Querques
  • , A. Scatizzi

Research output: Contribution to journalArticle

Abstract

Catheter obstruction due to fibrin deposits during CAPD can cause poor outflow of peritoneal fluid and recurrent peritonitis. In order to treat this complication, 75,000 IU of diluted Urokinase (UK) were infused into catheters obstructed by fibrin in 10 CAPD patients (4 of which had peritonitis), without adverse reactions. After 60 minutes, a 2 liter exchange of peritoneal fluid was performed. In all the cases a normal outflow was restored. Hemostasis parameters (PT, PTT, TT, Fibrinogen, FDP, Fibrin monomers, BT, AT III) and blood cells count (RBC, HGB, HCT, WBC, PTL), were assayed before and two hours after the UK infusion, and did not show any significant variation, except for a decrease of white blood cells, which remained, however, within the normal range. No peritonitis episode occurred in the follow-up period. UK fibrinolytic therapy is safe and effective in treating fibrin obstruction of CAPD catheters without catheter removal and prevents recurrent peritonitis.
Original languageEnglish
Pages (from-to)97-99
Number of pages3
JournalADVANCES IN PERITONEAL DIALYSIS
Volume5
Publication statusPublished - 1989

Keywords

  • Catheters, Indwelling
  • Female
  • Fibrin
  • Hemostasis
  • Humans
  • Infusions, Parenteral
  • Kidney Failure, Chronic
  • Male
  • Peritoneal Dialysis, Continuous Ambulatory
  • Peritonitis
  • Recurrence
  • Urokinase-Type Plasminogen Activator

Fingerprint

Dive into the research topics of 'A hemostasis study in CAPD patients during fibrinolytic intraperitoneal therapy with urokinase (UK)'. Together they form a unique fingerprint.

Cite this